Pathophysiological linkages of PD or other neurodegenerative diseases with CaV1.3 functions have been evidenced in multiple lines of studies (Guzman et al., 2009; Puopolo et al., 2007), including CaV1.3 antagonists as potential therapeutic interventions (Anekonda and Quinn, 2011; Pasternak et al., 2012; Triggle, 2007). This evidence concerns the gene CACNA1D and neurodegenerative disease.